«MAPS' highest priority project is sponsoring Food and Drug Administration (FDA) drug development research into 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of posttraumatic stress disorder (PTSD). FDA has designated MDMA-assisted therapy for PTSD a Breakthrough Therapy, and has come to agreement with MAPS on Phase 3 protocol designs after a rigorous Special Protocol Assessment (SPA) process. MAPS' goal is to develop MDMA-assisted therapy for PTSD into an FDA-approved prescription treatment. The Phase 3 trials are expected to be complete in 2022, meaning that FDA could approve the treatment as soon as 2023.» (source)
Your thoughts? Optimistic about the novel therapy, or think it'll fall flat, or something else?
At the time of writing, there are currently twenty clinical trials on PTSD, chronic PTSD and treatment resistant PTSD on clinicaltrials.gov, where they use MDMA-Assisted Psychotherapy.
Last edited by a moderator: